Boston Scientific Corporation has made a recommended cash offer for the entire issued share capital of BTG, at a price of approximately $4.2 billion (£3.3 billion).
The acquisition is intended to be implemented by way of a scheme of arrangement with financing in part by way of a £3.3 billion bridge credit agreement between Boston Scientific and Barclays Bank.